Goldman Sachs’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$54.9M Buy
652,590
+87,180
+15% +$6.33M 0.01% 1505
2025
Q4
$42.7M Sell
565,410
-34,206
-6% -$2.15M 0.01% 1640
2025
Q3
$23.8M Sell
599,616
-59,570
-9% -$2.27M ﹤0.01% 2099
2025
Q2
$28.6M Buy
659,186
+368,487
+127% +$14M ﹤0.01% 1802
2025
Q1
$10.9M Sell
290,699
-117,320
-29% -$4.54M ﹤0.01% 2621
2024
Q4
$18.5M Buy
408,019
+250,562
+159% +$12.8M ﹤0.01% 2204
2024
Q3
$9.25M Sell
157,457
-179,696
-53% -$8.61M ﹤0.01% 2810
2024
Q2
$13.3M Buy
337,153
+224,161
+198% +$10.9M ﹤0.01% 2239
2024
Q1
$7.51M Buy
112,992
+85,241
+307% +$3.72M ﹤0.01% 2742
2023
Q4
$775K Buy
27,751
+17,749
+177% +$356K ﹤0.01% 4526
2023
Q3
$213K Buy
+10,002
New +$220K ﹤0.01% 5024

Other funds holding APGE